(Q64379020)
Statements
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer (English)
P A Vasey
L N Shulman
S Campos
J Davis
M Gore
S Johnston
D H Kirn
V O'Neill
N Siddiqui
M V Seiden